Drug details

Soliris (eculizumab)

type of Monoclonal Antibodies, Complement Inhibitors

Soliris (eculizumab) is a monoclonal antibody that binds to proteins in the blood that can destroy red blood cells in people with a genetic condition that affects the natural defenses of red blood cells used to prevent the breakdown of red blood cells in people with paroxysmal nocturnal hemoglobinemia (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS).

This drug may have the following side effects:

• nausea,
• headache,
• vomiting,
• diarrhea,
• back pain, or
• tiredness,
• muscle pain,
• cold symptoms such as stuffy nose, sneezing, or sore throat.

The following drugs are related to Soliris, either as a replacement or used together:

• Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc injection)
• Empaveli (pegcetacoplan injection, for subcutaneous use)
• Uplizna (inebilizumab-cdon injection)
• Nyvepria (pegfilgrastim-apgf injection)
• Veopoz (pozelimab injection)
• Ultomiris (ravulizumab-cwvz injection)